» Articles » PMID: 32160710

A Dual-Functioning 5'-PPP-NS1shRNA That Activates a RIG-I Antiviral Pathway and Suppresses Influenza NS1

Overview
Publisher Cell Press
Date 2020 Mar 13
PMID 32160710
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Retinoic acid-inducible gene-I (RIG-I) is a cytosolic pathogen sensor that is crucial against a number of viral infections. Many viruses have evolved to inhibit pathogen sensors to suppress host innate immune responses. In the case of influenza, nonstructural protein 1 (NS1) suppresses RIG-I function, leading to viral replication, morbidity, and mortality. We show that silencing NS1 with in-vitro-transcribed 5'-triphosphate containing NS1 short hairpin RNA (shRNA) (5'-PPP-NS1shRNA), designed using the conserved region of a number of influenza viruses, not only prevented NS1 expression but also induced RIG-I activation and type I interferon (IFN) expression, resulting in an antiviral state leading to inhibition of influenza virus replication in vitro. In addition, administration of 5'-PPP-NS1shRNA in prophylactic and therapeutic settings resulted in significant inhibition of viral replication following viral challenge in vivo in mice with corresponding increases of RIG-I, IFN-β, and IFN-λ, as well as a decrease in NS1 expression.

Citing Articles

Antiviral strategies against influenza virus: an update on approved and innovative therapeutic approaches.

Bonomini A, Mercorelli B, Loregian A Cell Mol Life Sci. 2025; 82(1):75.

PMID: 39945883 PMC: 11825441. DOI: 10.1007/s00018-025-05611-1.


Antiviral Approaches against Influenza Virus.

Kumari R, Sharma S, Kumar A, Ende Z, Mishina M, Wang Y Clin Microbiol Rev. 2023; 36(1):e0004022.

PMID: 36645300 PMC: 10035319. DOI: 10.1128/cmr.00040-22.


Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma.

Shao L, Yu X, Han Q, Zhang X, Lu N, Zhang C Oncoimmunology. 2022; 11(1):2010894.

PMID: 36524206 PMC: 9746623. DOI: 10.1080/2162402X.2021.2010894.

References
1.
Szretter K, Balish A, Katz J . Influenza: propagation, quantification, and storage. Curr Protoc Microbiol. 2008; Chapter 15:Unit 15G.1. DOI: 10.1002/0471729256.mc15g01s3. View

2.
Lin L, Liu Q, Berube N, Detmer S, Zhou Y . 5'-Triphosphate-short interfering RNA: potent inhibition of influenza A virus infection by gene silencing and RIG-I activation. J Virol. 2012; 86(19):10359-69. PMC: 3457308. DOI: 10.1128/JVI.00665-12. View

3.
Heo Y . Baloxavir: First Global Approval. Drugs. 2018; 78(6):693-697. DOI: 10.1007/s40265-018-0899-1. View

4.
Juang Y, Lowther W, Kellum M, Au W, Lin R, Hiscott J . Primary activation of interferon A and interferon B gene transcription by interferon regulatory factor 3. Proc Natl Acad Sci U S A. 1998; 95(17):9837-42. PMC: 21423. DOI: 10.1073/pnas.95.17.9837. View

5.
Omoto S, Speranzini V, Hashimoto T, Noshi T, Yamaguchi H, Kawai M . Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil. Sci Rep. 2018; 8(1):9633. PMC: 6018108. DOI: 10.1038/s41598-018-27890-4. View